Press Release: Mapmygenome Launches Covisafe: A Superior Viral Sample Collection Kit

Press Release: MapmyGenome Launches Covisafe™ — A Superior Viral Sample Collection Kit

Hyderabad, September 1, 2020: MapmyGenome announces the launch of Covisafe™, a collection kit for COVID diagnostic testing. CSIR-Centre for Cellular and Molecular Biology validated and certified the kit to be as per ICMR protocols.

Key Advantages of Covisafe™

• Since the virus is rendered ineffective right after sampling, there is minimal risk to healthcare providers and staff after the sample is collected

• Samples can be transported safely at ambient temperatures — no cold-chain transport required

• Viral samples remain stable for up to 30 days at temperatures below 25°C, unlike VTM samples which must be transported to the testing lab on the same day

• Compatible with RNA extraction kits from standard providers such as Roche, Qiagen, and ThermoFisher — no preprocessing needed

• Does not use bovine or swine derived ingredients, recognising the unique cultural needs of India

MapmyGenome CEO Anu Acharya said: “Scaling up is the need of the hour and India needs more and more testing laboratories to churn out tests every day. Not only does the Covisafe kit reduce infection from live virus, it saves significant costs in terms of Personal Protective Equipment (PPE), cold-chain logistics, and downstream processing.”

About MapmyGenome

MapmyGenome® is India’s largest personal genomics company that encourages people to be proactive about their health. Founded in 2013, MapmyGenome started as India’s pioneering Personal Genomics Company with a vision to “Touch 100 million lives and save a million lives by 2030.” MapmyGenome was among the first private diagnostic labs to receive approval from Telangana State Government for COVID-19 testing.